Background Despite recent tx advances in R/M SCCHN, durable survival benefit remains an
elusive goal. CheckMate 651 (NCT02741570), a phase 3 randomized trial, evaluated N+ I …

PURPOSE CheckMate 651 (ClinicalTrials. gov identifier: NCT02741570) evaluated first-line
nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus …

Importance There remains an unmet need to improve clinical outcomes in patients with
recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) …

Simple Summary No real-world, long-term outcomes of immunotherapy with nivolumab for
recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have …

Abstract Background In the Phase‐III clinical trial, CheckMate 141, nivolumab significantly
improved survival versus standard of care in patients with platinum‐refractory …

Background: Treatment responses to immune checkpoint inhibitors may occur after initial
radiologic evidence of progression. In CheckMate 141 (NCT02105636), a randomized …

6009 Background: Patients (pts) with R/M SCCHN have poor prognosis, and median OS for
pts with platinum-refractory disease is≤ 6 mo. We investigated if nivo, a fully human IgG4 …

Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of
chemotherapy at the primary analysis of randomized, open‐label, phase 3 CheckMate 141 …

Background Patients (pts) with recurrent/metastatic (R/M) SCCHN have a poor prognosis.
Addition of cetuximab to platinum and 5-FU (Extreme regimen) improved overall survival …

6019 Background: In CheckMate 141, a randomized, phase 3 trial, nivo demonstrated
superior overall survival (OS) and better tolerability in patients (pts) with PR R/M SCCHN …